What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that acts as a growth hormone secretagogue (GHS) — a molecule that stimulates the pituitary gland to release growth hormone. It was developed by Novo Nordisk in the 1990s as part of research into GH secretagogues that could trigger GH release without the broader hormonal side effects seen in earlier-generation compounds like GHRP-6.
Mechanism of Action
Ipamorelin binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile growth hormone release — mimicking the body's natural GH-release pattern rather than causing a sustained elevation. This receptor is the same one activated by the hunger hormone ghrelin, which is part of why GH secretagogues like Ipamorelin are also associated with appetite changes.
The Founding Selectivity Study
Ipamorelin's reputation as the "selective" GH secretagogue comes from a specific, real study, not marketing language:
Raun et al., 1998 — European Journal of Endocrinology
"Ipamorelin, the first selective growth hormone secretagogue," published by researchers in Novo Nordisk's GH Biology department, characterized Ipamorelin's pharmacology in vitro and in vivo. The key finding: unlike GHRP-6 and GHRP-2 (older secretagogues), Ipamorelin did not significantly raise ACTH or cortisol beyond levels seen with GHRH stimulation alone. None of the secretagogues tested in the study — including Ipamorelin — affected FSH, LH, prolactin or TSH.
That combination — strong, selective GH release without the ACTH/cortisol spillover of older compounds — is the specific, citable basis for Ipamorelin's "selective" reputation in the research community, as opposed to a vaguer marketing claim.
Studied Benefits
🎯
Selective GH Release
Raun et al. 1998 found strong GH-releasing potency without significantly disturbing other pituitary hormones.
🧘
No Cortisol/ACTH Spike
Unlike GHRP-6 and GHRP-2, Ipamorelin didn't meaningfully raise stress-hormone markers in the founding study.
🔗
Pairs With GHRH Analogs
Frequently studied alongside CJC-1295, which acts on a separate receptor for a complementary GH-release pathway.
⚡
Pulsatile Release Pattern
Designed to mimic the body's natural pulsed GH secretion rather than a sustained artificial elevation.
Ipamorelin + CJC-1295
Ipamorelin is frequently studied and sold alongside CJC-1295, a GHRH (growth hormone releasing hormone) analog. The two work on different receptors — CJC-1295 on the GHRH receptor, Ipamorelin on the ghrelin receptor — so combining them is a common research design intended to amplify the pulsatile GH release from both pathways simultaneously. Controlled human trials of the specific combination (rather than each peptide individually) remain limited.
Dosing Guide
What the research data shows
No standardized, FDA-approved human dosage exists for Ipamorelin. Doses used in the founding pharmacology work were animal/in-vitro receptor-binding studies, not a human protocol.
| Context | Dose Reported | Source |
|---|
| In-vivo animal pharmacology | Variable µg/kg, dose-response receptor-binding design | Raun et al., Eur J Endocrinol, 1998 |
| Human protocol | Not established — no FDA-approved dose exists | — |
Compound X does not provide dosing recommendations. Ipamorelin is sold for laboratory research use only and is not intended for human consumption.
Reported Side Effects
Ipamorelin has not been evaluated in large-scale human trials as a standalone therapeutic, so its human safety data is more limited than compounds like MK-677 that have gone through formal clinical trials. Commonly reported research/anecdotal concerns include injection-site reactions, transient flushing, and — because it acts on the ghrelin/GH axis — theoretical long-term concerns about GH-axis effects that have not been fully characterized in controlled human studies.
FAQ
How is Ipamorelin different from CJC-1295?
They act on different receptors. CJC-1295 is a GHRH analog; Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. They're often studied together because they stimulate GH release through separate, complementary pathways.
Why is Ipamorelin called "selective"?
Because the 1998 Raun et al. study that characterized it found it released GH without significantly raising cortisol, ACTH, or other pituitary hormones the way older secretagogues like GHRP-6 did.
Is Ipamorelin FDA-approved?
No. Ipamorelin is not approved for any human use and is sold by research-chemical vendors labeled for laboratory research only.
References
Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. Additional Ipamorelin research is indexed on PubMed under "Ipamorelin growth hormone secretagogue" and "ghrelin receptor agonist pituitary."
